FIELD: medicine; pharmaceuticals.
SUBSTANCE: disclosed is a pharmaceutical composition for preventing or treating fatty liver disease, comprising as an active ingredient a pyrazole-based compound or a pharmaceutically acceptable salt thereof.
EFFECT: compound 3-phenyl-4-alkyl-1-(pyridin-2-yl)-1H-pyrazol-5-ol and its pharmaceutically acceptable salt are able to effectively inhibit fatty hepatosis, hepatic inflammation and hepatic fibrosis and are useful for preventing or treating NAFLD, in particular nonalcoholic steatohepatitis.
10 cl, 3 ex, 6 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| AGENT FOR PULMONARY FIBROSIS CONTAINING PYRAZOLE DERIVATIVE | 2021 |
|
RU2817989C1 |
| AGENT FOR TREATING ACUTE RENAL INJURY CAUSED BY CONTRAST AGENT | 2021 |
|
RU2817980C1 |
| COMPOSITION FOR PREVENTING OR TREATING FATTY LIVER DISEASES | 2015 |
|
RU2664696C2 |
| NEW CRYSTAL SOLID COMPOUND OF 3-PHENYL-4-PROPYL-1-(PYRIDINE-2-YL)-1H-PYRAZOL-5-OL HYDROCHLORIDE | 2018 |
|
RU2754255C2 |
| NOVEL PHARMACEUTICAL USE OF THIENO[3,2-D]PYRIMIDIN-4-ONE COMPOUNDS | 2019 |
|
RU2768828C1 |
| NOVEL PYRAZOLE DERIVATIVES | 2022 |
|
RU2816835C1 |
| TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE | 2019 |
|
RU2815647C2 |
| PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NON-ALCOHOLIC STEATHOEPATITIS | 2021 |
|
RU2803733C1 |
| USING LACTITOL AND AN ORAL DOSAGE FORM FOR TREATING AND PREVENTING NON-ALCOHOLIC FATTY LIVER DISEASE | 2018 |
|
RU2692243C1 |
| PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NON-ALCOHOLIC FATTY LIVER INFILTRATION, CONTAINING GPR119 LIGAND AS ACTIVE INGREDIENT | 2019 |
|
RU2768943C1 |
